EGFR and non-small cell lung carcinoma: PD-1/PD-L1 inhibitors in pretreated NSCLC showed a poor clinical benefit for patients with Epidermal Growth Factor Receptor (EGFR) mutation or Anaplastic Lymphoma Kinase (ALK) gene fusion.